公共咨询

医疗器械登记 到 ANVISA

按号码、产品、持有公司或CNPJ搜索,数据是ANVISA在公开数据中发布的,每天都会到达这里。

记录的 ROCHE DIAGNÓSTICA BRASIL LTDA取消

1,001 记录

产品持有公司班级有效性
PreciControl ClinChem Multi 110287410908ROCHE DIAGNÓSTICA BRASIL LTDAIII06/07/2036
PreciControl ClinChem Multi 210287410907ROCHE DIAGNÓSTICA BRASIL LTDAIII08/06/2036
PreciControl HSV10287410933ROCHE DIAGNÓSTICA BRASIL LTDAIII28/03/2036
PreciControl HbA1c norm10287410902ROCHE DIAGNÓSTICA BRASIL LTDAII现有
PreciControl HbA1c path10287410888ROCHE DIAGNÓSTICA BRASIL LTDAII现有
PreciControl ISD10287411025ROCHE DIAGNÓSTICA BRASIL LTDAIII02/12/2033
PreciControl Lp(a) Gen. 210287411033ROCHE DIAGNÓSTICA BRASIL LTDAII现有
PreciControl Maternal Care10287411567ROCHE DIAGNÓSTICA BRASIL LTDAIII08/06/2036
PreciControl Multimarker10287410915ROCHE DIAGNÓSTICA BRASIL LTDAII现有
PreciControl Syphilis10287411060ROCHE DIAGNÓSTICA BRASIL LTDAIV22/09/2034
PreciControl Thyro Sensitive10287411037ROCHE DIAGNÓSTICA BRASIL LTDAIII08/09/2036
PreciControl ThyroAB II10287411787ROCHE DIAGNÓSTICA BRASIL LTDAII现有
PreciControl Toxo IgG Avidity10287410971ROCHE DIAGNÓSTICA BRASIL LTDAIV14/05/2027
PreciControl Troponin10287410824ROCHE DIAGNÓSTICA BRASIL LTDAIII27/07/2034
PreciControl Universal Gen 210287410830ROCHE DIAGNÓSTICA BRASIL LTDAIII14/09/2034
PreciControl Varia10287410955ROCHE DIAGNÓSTICA BRASIL LTDAII现有
Precinorm U plus10287411600ROCHE DIAGNÓSTICA BRASIL LTDAIII06/06/2032
Precipath U plus10287411809ROCHE DIAGNÓSTICA BRASIL LTDAIII21/09/2036
Preciset Lp(a) Gen.210287411034ROCHE DIAGNÓSTICA BRASIL LTDAII现有
ProCell II M10287411234ROCHE DIAGNÓSTICA BRASIL LTDAI现有
ProGRP CalSet10287411016ROCHE DIAGNÓSTICA BRASIL LTDAII现有
Progesterone III Calset10287411184ROCHE DIAGNÓSTICA BRASIL LTDAII现有
Prostaglandin E1 Reagent10287410985ROCHE DIAGNÓSTICA BRASIL LTDAII现有
Protein C cobas t10287411481ROCHE DIAGNÓSTICA BRASIL LTDAII现有
QUIN2 Online TDM Quinidine_cobas c10287411568ROCHE DIAGNÓSTICA BRASIL LTDAIII06/10/2035

来源: ANVISA 开放数据,健康产品档案. 基础带来注册的有效性,而不是记录情况:注册可能在期限之前被取消,而不会在这里出现。 咨询门户 ANVISA.

接下来的步骤

您的产品需要在巴西注册

HSC在 ANVISA 中进行医疗器械登记,从风险类框架到过程跟踪。

联系专家